ArticleFrontiers in immunology2022

Association between immune-mediated adverse events and efficacy in metastatic non-small-cell lung cancer patients treated with durvalumab and tremelimumab.

Agnish Dey et al.PubMed ↗Full text ↗Publisher ↗

No numbers read from the abstract.